Cobalis Corp.

Legal opinion reinforces patent for anti-allergy medication

Published in Medical Patent Week, October 23rd, 2005

Cobalis Corp. (CLSC), a pharmaceutical biotech company developing anti-allergy medications, announced that intellectual property attorneys Knobbe Martens Olson & Bear LLP have issued an interpretation of the company's recent patent, defining its scope and outlining strict areas of infringement.

Cobalis currently is conducting clinical trials and recently announced positive preliminary Phase 3 clinical results for PreHistin, the over-the-counter anti-allergy medication the company is developing. Intended to be taken before the onset of allergy season, PreHistin is designed to prevent, rather than just relieve, allergy symptoms. U.S. Patent No. 6,255,294, entitled...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Patent Week

Source: Medical Patent Week (2005-10-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry